esketamine
Articles tagged with “esketamine”
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial found that pairing esketamine with 16 weeks of CBT reduced suicidal ideation and depression severity better than esketamine alone.
Ketamine Side Effects: What the Data Now Shows
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives ketamine patients a clearer picture of what to expect and when to switch.
Ketamine vs. Esketamine: Side Effects and Who Stops Treatment
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients make smarter choices about ketamine-based depression treatment.
Ketamine for TRD Works Better When Clinics Measure It
New research highlights how symptom tracking and dose optimization help treatment-resistant depression patients reach remission faster with ketamine.
Getting TRD Patients to Remission Faster in 2026
New analysis in Psychiatric Times shows measurement-based care and rapid dose adjustment get TRD patients to remission faster — here's what that means for ketamine.
How Active Clinical Management Speeds Up TRD Recovery
New analysis shows faster symptom tracking and dose adjustments lead to quicker TRD remission—here's what that means for ketamine therapy.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
Esketamine's Role in Treatment-Resistant Depression
Clinicians are turning to esketamine for TRD and suicidal depression. Here's what patients need to know about access, cost, and how it compares to IV ketamine.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Enantiomer: Definition and Relevance to Ketamine
A definition of enantiomers — mirror-image molecular forms — and their critical importance in understanding ketamine's two forms: esketamine (S-ketamine) and arketamine (R-ketamine).
Racemic Mixture: S-Ketamine and R-Ketamine Enantiomers Explained
A definition of racemic mixture in the context of ketamine therapy — explaining the S and R enantiomers, their different pharmacological profiles, and clinical implications.
Esketamine vs Racemic Ketamine: Understanding the Difference
A clinical comparison of esketamine (Spravato) and racemic ketamine, covering the S-enantiomer vs R/S mixture, FDA approval, efficacy data, cost, and practical considerations.
Racemic Ketamine vs Esketamine: Pharmacological Comparison
A detailed pharmacological comparison of racemic ketamine and esketamine (Spravato), covering efficacy, mechanisms, cost, access, and clinical decision-making.
Esketamine: The S-Enantiomer Behind Spravato
A glossary entry on esketamine, the S-enantiomer of ketamine marketed as Spravato, covering its pharmacology, FDA approval, and clinical significance.
FDA Esketamine (Spravato) Updates
A summary of the latest FDA regulatory actions, label updates, and clinical developments related to esketamine (Spravato) for depression treatment.
Intranasal Ketamine and Esketamine (Spravato)
A comprehensive guide to intranasal ketamine therapy, including the FDA-approved esketamine nasal spray Spravato — how it works, the REMS program, and clinical considerations.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.